scholarly article | Q13442814 |
P356 | DOI | 10.1136/EMERMED-2012-201996 |
P698 | PubMed publication ID | 23371977 |
P50 | author | Juan Gonzalez-Castillo | Q74128234 |
Francisco Javier Martín-Sánchez | Q82145877 | ||
P2093 | author name string | Pablo Herrero | |
Òscar Miró | |||
Pere Llorens | |||
Pascual Piñera | |||
Miquel Sánchez | |||
COPEP study investigators | |||
P2860 | cites work | Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE) | Q22242088 |
The TIMI Risk Score for Unstable Angina/Non–ST Elevation MI | Q22252998 | ||
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes | Q28306261 | ||
Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18. | Q33691730 | ||
Copeptin, IGFBP-1, and cardiovascular prognosis in patients with type 2 diabetes and acute myocardial infarction: a report from the DIGAMI 2 trial. | Q33932812 | ||
C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study | Q34003454 | ||
Incremental value of copeptin for rapid rule out of acute myocardial infarction | Q34018239 | ||
Copeptin improves early diagnosis of acute myocardial infarction | Q34113939 | ||
New biochemical markers in acute coronary syndromes | Q37184921 | ||
Novel biomarkers in cardiovascular disease: update 2010. | Q37799113 | ||
The long-term prognostic value of multiple biomarkers following a myocardial infarction. | Q40106701 | ||
C-terminal provasopressin (copeptin) is associated with left ventricular dysfunction, remodeling, and clinical heart failure in survivors of myocardial infarction | Q43795750 | ||
Multiple marker approach to risk stratification in patients with stable coronary artery disease | Q45573743 | ||
C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study | Q46061278 | ||
Copeptin, a stable peptide derived from the vasopressin precursor, is elevated in serum of sepsis patients | Q46515718 | ||
ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). | Q55036134 | ||
??? | Q22242895 | ||
P433 | issue | 4 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | acute coronary syndrome | Q266018 |
P304 | page(s) | 286-291 | |
P577 | publication date | 2013-01-31 | |
P1433 | published in | Emergency Medicine Journal | Q5370622 |
P1476 | title | The utility of copeptin in the emergency department as a predictor of adverse outcomes in non-ST-elevation acute coronary syndrome: the COPED-PAO study | |
P478 | volume | 31 |
Q58583594 | Association between Serum Copeptin and Stroke in Rural Areas of Northern China: A Matched Case-Control Study |
Q35556651 | Copeptin testing in acute myocardial infarction: ready for routine use? |
Q57101391 | Diagnostic accuracy of adding copeptin to cardiac troponin for non-ST-elevation myocardial infarction: A systematic review and meta-analysis |
Q38253152 | The prognostic value of copeptin in patients with acute chest pain |
Search more.